RESCEU: Defining the Burden of RSV Disease

Respiratory Syncytial Virus Infections Clinical Trial

Official title:

REspiratory Syncytial Virus Consortium in EUrope (RESCEU) Study: Defining the Burden of Respiratory Syncytial Virus (RSV) Disease.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03698084
• Other study ID #: 2017/01
• Status: Active, not recruiting
• Start date: September 5, 2017
• Est. completion date: November 30, 2026

Study information

• Verified date: October 2022
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational study will determine the burden of RSV disease in at least 2000 healthy infants over 6 years until November 2026. The study will determine the incidence of acute respiratory tract infection (ARTI) associated with RSV, of medically attended ARTI and RSV related hospitalisation. Mortality (RSV associated and all-cause) through all RSV seasons and the health care costs, resource use and Health Related Quality of Life will also be determined. The study also aims to determine important risk factors for RSV infection (by severity and healthcare utilisation.

Description:

Infants will be recruited into one of two cohorts: Passive (around 1800 participants) - Demographic data will be collected at inclusion and a parental questionnaire at one year of age. Infants admitted to a hospital with an acute respiratory tract illness will be followed up to the age of 3 years or 6 years with additional consent. Active (around 200 participants) - Demographic data, parental questionnaire and the following samples will be collected at inclusion; blood, nasopharyngeal swabs, urine and stool. During the infants first RSV season (Oct - May) weekly phone contact will monitor respiratory symptoms. Infants with respiratory symptoms associated with RSV (confirmed by point of care testing) will have further samples of blood, nasopharyngeal swabs, urine and stool collected at the time of infection and 7 weeks later. Infants in the active cohort will be followed up for up to 3 years or 6 years with additional consent.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 2000
• Est. completion date: November 30, 2026
• Est. primary completion date: November 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 12 Months

Eligibility

Inclusion Criteria:

• Healthy children, gestation age at least 37+0 weeks, born at participating centres.
• Written informed consent obtained from the mother.
• Parents able and willing to adhere to protocol-specified procedures (active cohort).

Exclusion Criteria:

• Major congenital defects or serious chronic illness (i.e. severe congenital heart and/or lung disease, genetic, immunologic and/or metabolic disorder).
• Gestational age of less than 37+0 weeks.
• Acute severe medical condition at moment of sampling (e.g. sepsis, severe asphyxia, for which the child is admitted to the hospital).
• Child in care.
• Parents not able to understand and communicate in the local language.
• Living outside catchment area of study sites.
• Mother vaccinated against RSV during pregnancy (by parental report).

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Respiratory Syncytial Virus Infections
• RSV Infection

Intervention

Procedure:
• venepuncture
sample collection for analysis
• nasopharyngeal swab
sample collection for analysis

Locations

Country	Name	City	State
United Kingdom	University of Oxford	Oxford	Oxfordshire

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of RSV associated Acute Respiratory Tract infections (ARTI) during the first year of life, to include the number of medically attended ARTI (MA-ARTI) and hospital admissions related to RSV.	RSV associated ARTI confirmed on nasopharyngeal swabs during home visits for all ARTI episodes during the RSV season, for testing using a RSV POC (Point of Care) test and reverse transcription-polymerase chain reaction (RT-PCR).; Participants will be screened for hospital admission for respiratory symptoms by parental questionnaire at age 1 year. If positive, RSV will be confirmed by accessing hospital records.; Medically attended RSV infection is defined as any medical care for RSV infection (defined as above)	Year 1
Primary	The relationship between infant RSV infection of different severity and school age asthma	Symptoms of asthma, diagnosis and use of asthma medication will be measured by parental questionnaire/medical records.	Year 4
Primary	The relationship between infant RSV infection of different severity and school age asthma	Symptoms of asthma, diagnosis and use of asthma medication will be measured by parental questionnaire/medical records.	Year 5
Primary	The relationship between infant RSV infection of different severity and school age asthma	Symptoms of asthma, diagnosis and use of asthma medication will be measured by parental questionnaire/medical records.	Year 6
Secondary	Wheeze symptoms up to 3 years of age following RSV infection of different severity	Parent reported wheeze and doctor diagnosis of wheeze by routine care (for active birth cohort and children of passive birth cohort admitted for ARTI).	Year 1 - 3
Secondary	Rate of all-cause medically attended (inpatient or outpatient) ARTI (active cohort).	Medically attended ARTI is defined as any medical care for a respiratory infection	Year 1
Secondary	RSV associated and all-cause mortality through all RSV seasons of follow up (passive and active cohorts).	Mortality through all RSV seasons of follow up including RSV-associated deaths and all cause deaths.	Year 1 - 3
Secondary	Health care costs and resource use	Health care utilisation for RSV-associated and all-cause medically attended (inpatient or outpatient) ARTI or respiratory events (active birth cohort).	Year 1 - 3
Secondary	Incidence of RSV-related secondary bacterial RTIs within 21 days after onset of RSV infection and their association with antibiotic use in hospitalized RSV ARTI patients and non-hospitalized RSV ARTI patients.	The incidence of RSV-associated secondary bacterial pneumonia and associated antibiotic consumption events within 21 days after onset of RSV-related symptoms.	Within 21 days of RSV infection
Secondary	To collect clinical samples (blood, nasopharyngeal, stool and urine) for biomarker analysis (active cohort).	Biomarkers associated with RSV infection in infants	Year 1
Secondary	Incidence rate of other respiratory pathogens (influenza, rhinovirus, human metapneumovirus, parainfluenzavirus, etc.) associated with all medically attended (inpatient or outpatient) ARTI (active cohort).	Additional viruses as detected by PCR testing on nasopharyngeal swab. Medically attended ARTI is defined as any medical care for a respiratory infection.	Year 1
Secondary	Risk factors for RSV infection (by severity and healthcare utilisation) (active and passive cohort).	Demographic risks factors as outlined in CRF/demographic questionnaires	Year 1 - 3
Secondary	The proportion of viral ARTI attributable to RSV (active cohort).	RSV and additional viruses as determined by PCR testing of nasopharyngeal swabs	Year 1
Secondary	Health Related Quality of Life in RSV-associated and all-cause medically attended ARTI patients and their families (active cohort).	Annual questionnaire to families to determine interruption of normal activities associated with RSV and all-cause medically attended ARTI (active cohort).	Year 1-3
Secondary	Risk factors for persistent wheeze at 3 and 6 years of age	Demographic and clinical parameters and outcomes from CRF/demographic questionnaires	Year 4,5 and 6